Frontier Medicines Reports 56% Response Rate in Phase 1 Lung Trial

The confirmed responses came in 10 of 18 evaluable patients with metastatic non-small cell lung cancer treated after chemotherapy and immunotherapy.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.